343
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer

, , , , &
Pages 531-537 | Received 10 Jan 2010, Accepted 21 Mar 2010, Published online: 13 Oct 2010

REFERENCES

  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
  • Kris MG, Natale RB, Herbst RS, : Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158.
  • Han SW, Kim TY, Hwang PG, : Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493–2501.
  • Zhang X, Chang A: Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci. 2008;5:209–217.
  • Chang A, Parikh P, Thongprasert S, : Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847–855.
  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, : Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132.
  • Lynch TJ, Bell DW, Sordella R, : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
  • Tsao MS, Sakurada A, Cutz JC, : Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144.
  • Takano T, Ohe Y, Sakamoto H, : Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829–6837.
  • Shigematsu H, Lin L, Takahashi T, : Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346.
  • Fukuoka M, Yano S, Giaccone G, : Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237–2246.
  • Miller VA, Kris MG, Shah N, : Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103–1109.
  • Wu YL, Zhong WZ, Li LY, : Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007;2: 430–439.
  • Mu XL, Li LY, Zhang XT, : Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:4289–4294.
  • Endoh H, Ishibashi Y, Yamaki E, : Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer. 2009;63:241–246.
  • Levkowitz G, Waterman H, Ettenberg SA, : Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029–1040.
  • Mosesson Y, Shtiegman K, Katz M, : Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem. 2003;278:21323–21326.
  • Chen YR, Fu YN, Lin CH, : Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene. 2006;25:1205–1215.
  • Han W, Zhang T, Yu H, Foulke JG, Tang CK: Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther. 2006;5:1361–1368.
  • VanMeter AJ, Rodriguez AS, Bowman ED, : Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics. 2008;7:1902–1924.
  • Okabe T, Okamoto I, Tamura K, : Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 2007;67:2046–2053.
  • Turner BC, Krajewski S, Krajewska M, : BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001;19:992–1000.
  • Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46:685–693.
  • Morita S, Okamoto I, Kobayashi K, : Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493–4498.
  • Sequist LV, Martins RG, Spigel D, : First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26: 2442–2449.
  • He C, Liu M, Zhou C, : Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small cell lung cancer. Int J Cancer. 2009;125:2393–2399.
  • Shih JY, Gow CH, Yu CJ, : Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2006;118:963–969.
  • Yu J, Kane S, Wu J, : Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023–3028.
  • Sordella R, Bell DW, Haber DA, Settleman J.: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–1167.
  • Furukawa M, Nagatomo I, Kumagai T, : Gefitinib-sensitive EGFR lacking residues 746–750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. DNA Cell Biol. 2007;26:178–185.
  • Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM: Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study. BMC Cancer. 2009;9:333.
  • Hijiya N, Miyawaki M, Kawahara K, : Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol. 2008;39:316–323.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.